ATE417604T1 - Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe - Google Patents

Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe

Info

Publication number
ATE417604T1
ATE417604T1 AT97935184T AT97935184T ATE417604T1 AT E417604 T1 ATE417604 T1 AT E417604T1 AT 97935184 T AT97935184 T AT 97935184T AT 97935184 T AT97935184 T AT 97935184T AT E417604 T1 ATE417604 T1 AT E417604T1
Authority
AT
Austria
Prior art keywords
sustained release
high dose
insoluble drugs
release matrix
dose insoluble
Prior art date
Application number
AT97935184T
Other languages
English (en)
Inventor
Anand Baichwal
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Application granted granted Critical
Publication of ATE417604T1 publication Critical patent/ATE417604T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT97935184T 1996-07-08 1997-07-08 Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe ATE417604T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2133596P 1996-07-08 1996-07-08

Publications (1)

Publication Number Publication Date
ATE417604T1 true ATE417604T1 (de) 2009-01-15

Family

ID=21803631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935184T ATE417604T1 (de) 1996-07-08 1997-07-08 Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe

Country Status (12)

Country Link
US (4) US6093420A (de)
EP (1) EP0859603B1 (de)
JP (1) JP3148256B2 (de)
KR (1) KR100321489B1 (de)
AT (1) ATE417604T1 (de)
AU (1) AU695734B2 (de)
CA (1) CA2231195C (de)
DE (1) DE69739165D1 (de)
ES (1) ES2322405T3 (de)
IL (1) IL123505A (de)
MX (1) MX9801835A (de)
WO (1) WO1998001117A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
MX9801835A (es) * 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
CA2301304A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
ATE245451T1 (de) * 1998-04-07 2003-08-15 Alcon Lab Inc Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
KR100463496B1 (ko) * 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 고가용성 약물용 서방성 메트리스 시스템
US20050037073A1 (en) * 2000-01-13 2005-02-17 Alpharx Inc. Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030190360A1 (en) * 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
PL207748B1 (pl) * 2001-07-06 2011-01-31 Penwest Pharmaceuticals Company Preparat o przedłużonym uwalnianiu zawierający oksymorfon oraz jego zastosowanie
EP1414458B1 (de) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US6705028B2 (en) * 2001-09-12 2004-03-16 Honda Giken Kogyo Kabushiki Kaisha Self-propelled snowplow vehicle
EP1429730A4 (de) * 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan Opioid-formulierungen mit verringertem missbrauchspotenzial
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
WO2003066021A2 (en) 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
WO2004012715A1 (en) 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
ATE404175T1 (de) * 2003-03-31 2008-08-15 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
KR20060093334A (ko) * 2003-10-17 2006-08-24 가부시키가이샤 메드렉스 비구아니드계 약제를 함유하는 젤리 제제
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1906932A2 (de) * 2005-06-29 2008-04-09 Panacea Biotec Ltd. Pharmazeutische zusammensetzungen mit modifizierter freisetzung auf der basis von zwei polymeren und herstellungsprozesse dazu
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007069874A1 (en) * 2005-12-16 2007-06-21 Hanmi Pharm. Co., Ltd. Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
GB2438287A (en) * 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US9023381B2 (en) * 2007-01-26 2015-05-05 Michelle Chow Enhanced medicinal delivery system processes and products thereby especially useful for children
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
MX2011007819A (es) * 2009-01-22 2011-12-16 Abbott Healthcare Private Ltd Composicion farmaceutica cronoterapeutica.
TW201105316A (en) 2009-07-22 2011-02-16 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
EP3003283A1 (de) 2013-05-29 2016-04-13 Grünenthal GmbH Manipulationssichere darreichungsform mit bimodalem freisetzungsprofil
CA2917136C (en) 2013-07-12 2022-05-31 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
AU2015266117A1 (en) * 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3285745A1 (de) 2015-04-24 2018-02-28 Grünenthal GmbH Manipulationssichere darreichungsform mit sofortiger freisetzung und widerstand gegen lösungsmittelextraktion
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20210401775A1 (en) * 2018-11-02 2021-12-30 Amaterasu Lifesciences Llp A liquid injectable composition
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
SU432703A3 (de) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
JPS60139688A (ja) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd 無定形ジヒドロピリジン粉末製剤
DE3400106A1 (de) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
AU4064285A (en) * 1984-03-21 1985-10-11 American Home Products Corporation Sustained release pharmaceutical capsules
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
GB8608818D0 (en) * 1986-04-11 1986-05-14 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3682208D1 (de) * 1986-12-18 1991-11-28 Kurt Heinz Bauer Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
WO1989008446A1 (en) * 1988-03-09 1989-09-21 Snow Brand Milk Products Co., Ltd. Suspended-release preparation prepared by using alginic acid
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
JPH10509982A (ja) * 1994-12-01 1998-09-29 サイバス ファーマシューティカル，インコーポレイティド 高等植物から獲得できる粉末ヒドロコロイドゴムを利用するｎｓａｉｄの導入
MX9801835A (es) * 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
US5845563A (en) * 1997-01-10 1998-12-08 Sunbeam Products, Inc. Rotisserie cooker
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation

Also Published As

Publication number Publication date
IL123505A0 (en) 1998-10-30
KR19990044486A (ko) 1999-06-25
US6093420A (en) 2000-07-25
AU695734B2 (en) 1998-08-20
US20010021392A1 (en) 2001-09-13
US6245355B1 (en) 2001-06-12
JPH10511407A (ja) 1998-11-04
IL123505A (en) 2004-12-15
AU3818397A (en) 1998-02-02
WO1998001117A1 (en) 1998-01-15
CA2231195C (en) 2003-01-21
EP0859603B1 (de) 2008-12-17
KR100321489B1 (ko) 2002-10-09
ES2322405T3 (es) 2009-06-19
EP0859603A1 (de) 1998-08-26
US6689386B2 (en) 2004-02-10
JP3148256B2 (ja) 2001-03-19
CA2231195A1 (en) 1998-01-15
DE69739165D1 (de) 2009-01-29
EP0859603A4 (de) 2006-05-24
MX9801835A (es) 1998-08-30
US20040121012A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ATE417604T1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
FI961996A (fi) Pitkitetysti vapauttavat valmisteet metoprololin 24 tunnin pituiseksi vapauttamiseksi
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
BR9908438A (pt) Tabletes de desintegração rápida
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
AR032293A1 (es) Estuche farmaceutico
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
ES2166988T3 (es) Terapia de administracion uniforme de farmacos.
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
TR200201071T2 (tr) Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi
ES2184452T3 (es) Preparacion farmaceutica que contiene levotiroxina de sodio.
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.
ES2180737T3 (es) Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos.
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
TR199800765T2 (xx) Otoim�n hastal�klar�n tedavisine mahsus bir farmas�tik bile�im
ES2141978T3 (es) Retinoides triciclicos, metodos para su produccion y uso.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties